FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS Genet / Allelic Variation in CXCL16 Determines CD3+ T Lymphocyte Sus...
PLoS genetics2016; 12(12); e1006467; doi: 10.1371/journal.pgen.1006467

Allelic Variation in CXCL16 Determines CD3+ T Lymphocyte Susceptibility to Equine Arteritis Virus Infection and Establishment of Long-Term Carrier State in the Stallion.

Abstract: Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA), a respiratory, systemic, and reproductive disease of horses and other equid species. Following natural infection, 10-70% of the infected stallions can become persistently infected and continue to shed EAV in their semen for periods ranging from several months to life. Recently, we reported that some stallions possess a subpopulation(s) of CD3+ T lymphocytes that are susceptible to in vitro EAV infection and that this phenotypic trait is associated with long-term carrier status following exposure to the virus. In contrast, stallions not possessing the CD3+ T lymphocyte susceptible phenotype are at less risk of becoming long-term virus carriers. A genome wide association study (GWAS) using the Illumina Equine SNP50 chip revealed that the ability of EAV to infect CD3+ T lymphocytes and establish long-term carrier status in stallions correlated with a region within equine chromosome 11. Here we identified the gene and mutations responsible for these phenotypes. Specifically, the work implicated three allelic variants of the equine orthologue of CXCL16 (EqCXCL16) that differ by four non-synonymous nucleotide substitutions (XM_00154756; c.715 A → T, c.801 G → C, c.804 T → A/G, c.810 G → A) within exon 1. This resulted in four amino acid changes with EqCXCL16S (XP_001504806.1) having Phe, His, Ile and Lys as compared to EqCXL16R having Tyr, Asp, Phe, and Glu at 40, 49, 50, and 52, respectively. Two alleles (EqCXCL16Sa, EqCXCL16Sb) encoded identical protein products that correlated strongly with long-term EAV persistence in stallions (P<0.000001) and are required for in vitro CD3+ T lymphocyte susceptibility to EAV infection. The third (EqCXCL16R) was associated with in vitro CD3+ T lymphocyte resistance to EAV infection and a significantly lower probability for establishment of the long-term carrier state (viral persistence) in the male reproductive tract. EqCXCL16Sa and EqCXCL16Sb exert a dominant mode of inheritance. Most importantly, the protein isoform EqCXCL16S but not EqCXCL16R can function as an EAV cellular receptor. Although both molecules have equal chemoattractant potential, EqCXCL16S has significantly higher scavenger receptor and adhesion properties compared to EqCXCL16R.
Get Full Text
Publication Date: 2016-12-08 PubMed ID: 27930647PubMed Central: PMC5145142DOI: 10.1371/journal.pgen.1006467Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper is about how difference in genetic makeup, specifically variations in the CXCL16 gene, affects the susceptibility of horse T-cells to equine arteritis virus (EAV) infection, influencing the long-term carrier status in stallions.

Objective of the Research

  • The primary goal of this study was to identify and understand the genetic factors that enable some stallions to become long-term carriers of equine arteritis virus (EAV) after exposure. Additionally, the researchers aimed to shed light on the mechanism behind the susceptibility of certain T-lymphocytes to EAV infection.

Methodology and Findings

  • The study used a genome-wide association study (GWAS) and found that the ability of EAV to infect CD3+ T-cells and establish long-term carriage in stallions was linked with a region in chromosome 11 of equines.
  • Researchers pinpointed the equine orthologue of the CXCL16 gene (EqCXCL16), identifying three allelic variants with four non-synonymous nucleotide substitutions within exon 1. These changes caused four amino acid differences.
  • The two alleles (EqCXCL16Sa, EqCXCL16Sb) produced identical proteins and were heavily associated with persistent EAV infection in stallions. These alleles also enabled CD3+ T-cell susceptibility to EAV infection in vitro.
  • The third allele variant (EqCXCL16R) was linked with resistance to EAV infection in CD3+ T-cells in vitro and a significantly lower chance of establishing a long-term carrier state in the male reproductive tract.

Implications and Significance

  • These results indicate that the allele variants of the EqCXCL16 gene function in a dominant manner and have a significant role in dictating the long-term carrier state of EAV in stallions.
  • The researchers established that the protein isoform EqCXCL16S can serve as a cellular receptor for EAV, unlike EqCXCL16R.
  • Between the two variants, EqCXCL16S exhibited a greater scavenger receptor and adhesive capacity compared to EqCXCL16R, despite having equivalent chemoattraction potential. This suggests that differences in the allelic variants of the EqCXCL16 gene can influence the physiological responses of CD3+ T-cells to EAV infection.

Cite This Article

APA
Sarkar S, Bailey E, Go YY, Cook RF, Kalbfleisch T, Eberth J, Chelvarajan RL, Shuck KM, Artiushin S, Timoney PJ, Balasuriya UB. (2016). Allelic Variation in CXCL16 Determines CD3+ T Lymphocyte Susceptibility to Equine Arteritis Virus Infection and Establishment of Long-Term Carrier State in the Stallion. PLoS Genet, 12(12), e1006467. https://doi.org/10.1371/journal.pgen.1006467

Publication

PLoS genetics
ISSN: 1553-7404
NlmUniqueID: 101239074
Country: United States
Language: English
Volume: 12
Issue: 12
Pages: e1006467

Researcher Affiliations

Sarkar, Sanjay
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Bailey, Ernest
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Go, Yun Young
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Cook, R Frank
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Kalbfleisch, Ted
  • Department of Biochemistry and Molecular Genetics, School of Medicine, University of Louisville, Louisville, Kentucky, United States of America.
Eberth, John
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Chelvarajan, R Lakshman
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Shuck, Kathleen M
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Artiushin, Sergey
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Timoney, Peter J
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.
Balasuriya, Udeni B R
  • Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, United States of America.

MeSH Terms

  • Alleles
  • Amino Acid Sequence / genetics
  • Animals
  • Arterivirus Infections / genetics
  • Arterivirus Infections / veterinary
  • Arterivirus Infections / virology
  • CD3 Complex / genetics
  • CD3 Complex / immunology
  • Chemokines, CXC / genetics
  • Equartevirus / genetics
  • Equartevirus / pathogenicity
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Horse Diseases / genetics
  • Horse Diseases / virology
  • Horses / genetics
  • Horses / virology
  • Male
  • Phylogeny
  • Semen / metabolism
  • T-Lymphocytes / immunology
  • T-Lymphocytes / pathology

Conflict of Interest Statement

The authors have declared that no competing interests exist.

References

This article includes 76 references
  1. Snijder EJ, Kikkert M. Arteriviruses. Fields Virology 2013 p. 859–79.
  2. Balasuriya UB, Go YY, MacLachlan NJ. Equine arteritis virus. Vet Microbiol 2013;167(1–2):93–122.
    doi: 10.1016/j.vetmic.2013.06.015pmc: PMC7126873pubmed: 23891306google scholar: lookup
  3. Snijder EJ, Kikkert M, Fang Y. Arterivirus molecular biology and pathogenesis. J Gen Virol 2013;94(Pt 10):2141–63.
    doi: 10.1099/vir.0.056341-0pubmed: 23939974google scholar: lookup
  4. Doll ER, Bryans JT, McCollum WH, Crowe ME. Isolation of a filterable agent causing arteritis of horses and abortion by mares; its differentiation from the equine abortion (influenza) virus. The Cornell veterinarian 1957;47(1):3–41.
    pubmed: 13397177
  5. Balasuriya UB. Equine viral arteritis. Vet Clin North Am Equine Pract 2014;30(3):543–60.
    doi: 10.1016/j.cveq.2014.08.011pubmed: 25441113google scholar: lookup
  6. McCollum WH, Timoney PJ, Lee JW Jr, Habacker PL, Balasuriya UBR, MacLachlan NJ. Features of an outbreak of equine viral arteritis on a breeding farm associated with abortion and fatal interstitial pneumonia in neonatal foals. Proceeding of the 8th International Conference on Equine Infectious Diseases 1998; Dubai.
  7. McCollum WH, Timoney PJ. Experimental observations on the virulence of isolates of equine arteritis virus. Proceedings of the 8th International Conference Equine Infectious Diseases 1998; Dubai.
  8. Timoney PJ, McCollum WH. Equine viral arteritis. Vet Clin North Am Equine Pract 1993;9(2):295–309.
    pmc: PMC7134676pubmed: 8395325
  9. Vaala WE, Hamir AN, Dubovi EJ, Timoney PJ, Ruiz B. Fatal, congenitally acquired infection with equine arteritis virus in a neonatal thoroughbred. Equine Vet J 1992;24(2):155–8.
    pubmed: 1316264
  10. Balasuriya UBR, Sarkar S, Carossino M, Go YY, Chelvarajan L, Cook RF, Loynachan AT, Timoney PJ, Bailey E. Host factors that contribute to equine arteritis virus persistence in the stallion: An update. J Equine Vet Sci 2016;43. Epub S17.
  11. Neu SM, Timoney PJ, McCollum WH. Persistent infection of the reproductive tract in stallions experimentally infected with equine arteritis virus. Proceedings of the 5th International Conference on Equine Infectious Diseases 1987; Lexington, Kentucky.
  12. Guthrie AJ, Howell PG, Hedges JF, Bosman AM, Balasuriya UB, McCollum WH. Lateral transmission of equine arteritis virus among Lipizzaner stallions in South Africa. Equine Vet J 2003;35(6):596–600.
    pubmed: 14515961
  13. Little TV, Holyoak GR, McCollum WH, Timoney PJ. Output of equine arteritis virus from persistently infected stallions is testosterone dependent. Proceedings of the 6th International Conference on Equine Infectious Diseases 1992: R&W Publications, Newmarket, England.
  14. McCollum WH, Little TV, Timoney PJ, Swerczek TW. Resistance of castrated male horses to attempted establishment of the carrier state with equine arteritis virus. J Comp Pathol 1994;111(4):383–8.
    pubmed: 7884055
  15. Neu SM, Timoney PJ, McCollum WH. Persistent infection of the reproductive tract in stallions experimentally infected with equine arteritis virus. Proceedings of the 5th International Conference Equine infectious diseases 1987 1988; Lexington, Kentucky: The University Press of Kentucky.
  16. Miszczak F, Legrand L, Balasuriya UB, Ferry-Abitbol B, Zhang J, Hans A. Emergence of novel equine arteritis virus (EAV) variants during persistent infection in the stallion: origin of the 2007 French EAV outbreak was linked to an EAV strain present in the semen of a persistently infected carrier stallion. Virology 2012;423(2):165–74.
    doi: 10.1016/j.virol.2011.11.028pubmed: 22209234google scholar: lookup
  17. Balasuriya UB, Hedges JF, Nadler SA, McCollum WH, Timoney PJ, MacLachlan NJ. Genetic stability of equine arteritis virus during horizontal and vertical transmission in an outbreak of equine viral arteritis. J Gen Virol 1999;80 (Pt 8):1949–58.
    pubmed: 10466790
  18. Broaddus CC, Balasuriya UB, Timoney PJ, White JL, Makloski C, Torrisi K. Infection of embryos following insemination of donor mares with equine arteritis virus infective semen. Theriogenology 2011;76(1):47–60.
    doi: 10.1016/j.theriogenology.2011.01.017pubmed: 21345485google scholar: lookup
  19. Go YY, Zhang J, Timoney PJ, Cook RF, Horohov DW, Balasuriya UB. Complex interactions between the major and minor envelope proteins of equine arteritis virus determine its tropism for equine CD3+ T lymphocytes and CD14+ monocytes. J Virol 2010;84(10):4898–911.
    doi: 10.1128/JVI.02743-09pmc: PMC2863813pubmed: 20219931google scholar: lookup
  20. Go YY, Bailey E, Cook FR, Coleman SJ, Macleod JN, Chen KC. Genome-wide association study among four horse breeds identifies a common haplotype associated with in vitro CD3+ T cell susceptibility/resistance to equine arteritis virus infection. J Virol 2011;85(24):13174–84.
    doi: 10.1128/JVI.06068-11pmc: PMC3233183pubmed: 21994447google scholar: lookup
  21. Go YY, Bailey E, Timoney PJ, Shuck KM, Balasuriya UB. Evidence that in vitro susceptibility of CD3+ T lymphocytes to equine arteritis virus infection reflects genetic predisposition of naturally infected stallions to become carriers of the virus. J Virol 2012;86(22):12407–10.
    doi: 10.1128/JVI.01698-12pmc: PMC3486460pubmed: 22933293google scholar: lookup
  22. Timoney PJ, McCollum WH, Murphy TW, Roberts AW, Willard JG, Carswell GD. The carrier state in equine arteritis virus infection in the stallion with specific emphasis on the venereal mode of virus transmission. J Reprod Fertil Suppl 1987;35:95–102.
    pubmed: 2824772
  23. Sarkar S, Chelvarajan L, Go YY, Cook F, Artiushin S, Mondal S. Equine Arteritis Virus Uses Equine CXCL16 as an Entry Receptor. J Virol 2016;90(7):3366–84.
    doi: 10.1128/JVI.02455-15pmc: PMC4794689pubmed: 26764004google scholar: lookup
  24. Mondal SP, Cook RF, Chelvarajan RL, Henney PJ, Timoney PJ, Balasuriya UB. Development and characterization of a synthetic infectious cDNA clone of the virulent Bucyrus strain of equine arteritis virus expressing mCherry (red fluorescent protein). Arch Virol 2016;161(4):821–32.
    doi: 10.1007/s00705-015-2633-6pubmed: 26711457google scholar: lookup
  25. Sheikine Y, Sirsjo A. CXCL16/SR-PSOX—a friend or a foe in atherosclerosis?. Atherosclerosis 2008;197(2):487–95.
    doi: 10.1016/j.atherosclerosis.2007.11.034pubmed: 18191863google scholar: lookup
  26. Prabhudas M, Bowdish D, Drickamer K, Febbraio M, Herz J, Kobzik L. Standardizing scavenger receptor nomenclature. J Immunol 2014;192(5):1997–2006.
    doi: 10.4049/jimmunol.1490003pmc: PMC4238968pubmed: 24563502google scholar: lookup
  27. Shimaoka T, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004;75(2):267–74.
    doi: 10.1189/jlb.1003465pubmed: 14634054google scholar: lookup
  28. Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von Hundelshausen P. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007;178(12):8064–72.
    pubmed: 17548644
  29. van der Voort R, Verweij V, de Witte TM, Lasonder E, Adema GJ, Dolstra H. An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells. J Leukoc Biol 2010;87(6):1029–39.
    doi: 10.1189/jlb.0709482pmc: PMC3210559pubmed: 20181724google scholar: lookup
  30. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004;172(10):6362–72.
    pubmed: 15128827
  31. Hofnagel O, Luechtenborg B, Plenz G, Robenek H. Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. Arterioscler Thromb Vasc Biol 2002;22(4):710–1.
    pubmed: 11950715
  32. Shashkin P, Simpson D, Mishin V, Chesnutt B, Ley K. Expression of CXCL16 in human T cells. Arterioscler Thromb Vasc Biol 2003;23(1):148–9.
    pubmed: 12524239
  33. Tabata S, Kadowaki N, Kitawaki T, Shimaoka T, Yonehara S, Yoshie O. Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells. J Leukoc Biol 2005;77(5):777–86.
    doi: 10.1189/jlb.1204733pubmed: 15703197google scholar: lookup
  34. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000;275(52):40663–6.
    doi: 10.1074/jbc.C000761200pubmed: 11060282google scholar: lookup
  35. Tohyama M, Sayama K, Komatsuzawa H, Hanakawa Y, Shirakata Y, Dai X. CXCL16 is a novel mediator of the innate immunity of epidermal keratinocytes. Int Immunol 2007;19(9):1095–102.
    doi: 10.1093/intimm/dxm083pubmed: 17855433google scholar: lookup
  36. Wuttge DM, Zhou X, Sheikine Y, Wagsater D, Stemme V, Hedin U. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24(4):750–5.
    doi: 10.1161/01.ATV.0000124102.11472.36pubmed: 14988089google scholar: lookup
  37. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P. Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001;166(8):5145–54.
    pubmed: 11290797
  38. Day C, Patel R, Guillen C, Wardlaw AJ. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Experimental lung research 2009;35(4):272–83.
    doi: 10.1080/01902140802635517pmc: PMC2685639pubmed: 19415545google scholar: lookup
  39. Lougaris V, Baronio M, Vitali M, Tampella G, Soresina A, Badolato R. B cell responses to CpG correlate with CXCL16 expression levels in common variable immunodeficiency. TheScientificWorldJournal 2012;2012:960219.
    doi: 10.1100/2012/960219pmc: PMC3289902pubmed: 22454615google scholar: lookup
  40. Meyer Dos Santos S, Blankenbach K, Scholich K, Dorr A, Monsefi N, Keese M. Platelets from flowing blood attach to the inflammatory chemokine CXCL16 expressed in the endothelium of the human vessel wall. Thrombosis and haemostasis 2015;114(2):297–312.
    doi: 10.1160/TH14-11-0911pubmed: 25904061google scholar: lookup
  41. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. The Journal of clinical investigation 2001;107(5):595–601.
    doi: 10.1172/JCI11902pmc: PMC199429pubmed: 11238560google scholar: lookup
  42. Latta M, Mohan K, Issekutz TB. CXCR6 is expressed on T cells in both T helper type 1 (Th1) inflammation and allergen-induced Th2 lung inflammation but is only a weak mediator of chemotaxis. Immunology 2007;121(4):555–64.
    doi: 10.1111/j.1365-2567.2007.02603.xpmc: PMC2265962pubmed: 17437534google scholar: lookup
  43. Petit SJ, Chayen NE, Pease JE. Site-directed mutagenesis of the chemokine receptor CXCR6 suggests a novel paradigm for interactions with the ligand CXCL16. Eur J Immunol 2008;38(8):2337–50.
    doi: 10.1002/eji.200838269pubmed: 18629940google scholar: lookup
  44. Petit SJ, Wise EL, Chambers JC, Sehmi J, Chayen NE, Kooner JS. The CXCL16 A181V mutation selectively inhibits monocyte adhesion to CXCR6 but is not associated with human coronary heart disease. Arterioscler Thromb Vasc Biol 2011;31(4):914–20.
    doi: 10.1161/ATVBAHA.110.220558pubmed: 21233446google scholar: lookup
  45. Sarkar S, Chelvarajan L, Go YY, Cook F, Artuishin S, Mondal S. Equine Arteritis Virus Uses Equine CXCL16 (EqCXCL16) as an Entry Receptor. Journal of virology 2016.
    pmc: PMC4794689pubmed: 26764004
  46. Landro L, Damas JK, Halvorsen B, Fevang B, Ueland T, Otterdal K. CXCL16 in HIV infection—a link between inflammation and viral replication. Eur J Clin Invest 2009;39(11):1017–24.
    doi: 10.1111/j.1365-2362.2009.02207.xpubmed: 19674076google scholar: lookup
  47. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013;4:1795.
    doi: 10.1038/ncomms2766pmc: PMC3649763pubmed: 23653207google scholar: lookup
  48. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK 3rd. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006;54(3):765–78.
    doi: 10.1002/art.21662pmc: PMC1472704pubmed: 16508941google scholar: lookup
  49. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007;49(4):442–9.
    doi: 10.1016/j.jacc.2006.09.034pubmed: 17258089google scholar: lookup
  50. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams DH. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005;174(2):1055–62.
    pubmed: 15634930
  51. Jovanovic I, Zivkovic M, Djuric T, Popovic M, Alavantic D, Stankovic A. CXCL16 in Vascular Pathology Research: from Macro Effects to microRNAs. J Atheroscler Thromb 2015;22(10):1012–24.
    doi: 10.5551/jat.29942pubmed: 26289084google scholar: lookup
  52. Lu Z, Sarkar S, Zhang J, Balasuriya UB. Conserved arginine residues in the carboxyl terminus of the equine arteritis virus E protein may play a role in heparin binding but may not affect viral infectivity in equine endothelial cells. Arch Virol 2016.
    pubmed: 26739582
  53. Go YY, Cook RF, Fulgencio JQ, Campos JR, Henney P, Timoney PJ. Assessment of correlation between in vitro CD3+ T cell susceptibility to EAV infection and clinical outcome following experimental infection. Vet Microbiol 2012;157(1–2):220–5.
    doi: 10.1016/j.vetmic.2011.11.031pubmed: 22177968google scholar: lookup
  54. Balasuriya UB, Hedges JF, Smalley VL, Navarrette A, McCollum WH, Timoney PJ. Genetic characterization of equine arteritis virus during persistent infection of stallions. J Gen Virol 2004;85(Pt 2):379–90.
    doi: 10.1099/vir.0.19545-0pubmed: 14769895google scholar: lookup
  55. Hedges JF, Balasuriya UB, Timoney PJ, McCollum WH, MacLachlan NJ. Genetic divergence with emergence of novel phenotypic variants of equine arteritis virus during persistent infection of stallions. J Virol 1999;73(5):3672–81.
    pmc: PMC104142pubmed: 10196259
  56. Huang M, Han Y, Zhang X, Pei F, Deng J, Kang J. An intron polymorphism in the CXCL16 gene is associated with increased risk of coronary artery disease in Chinese Han population: a large angiography-based study. Atherosclerosis 2010;210(1):160–5.
    doi: 10.1016/j.atherosclerosis.2009.11.004pubmed: 19954776google scholar: lookup
  57. Lundberg GA, Kellin A, Samnegard A, Lundman P, Tornvall P, Dimmeler S. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. J Intern Med 2005;257(5):415–22.
    doi: 10.1111/j.1365-2796.2005.01469.xpubmed: 15836657google scholar: lookup
  58. Zivkovic M, Djuric T, Stojkovic L, Jovanovic I, Koncar I, Davidovic L. CXCL16 haplotypes in patients with human carotid atherosclerosis: preliminary results. J Atheroscler Thromb 2015;22(1):10–20.
    doi: 10.5551/jat.24299pubmed: 25142184google scholar: lookup
  59. Balasuriya UB, Snijder EJ, Heidner HW, Zhang J, Zevenhoven-Dobbe JC, Boone JD. Development and characterization of an infectious cDNA clone of the virulent Bucyrus strain of Equine arteritis virus. J Gen Virol 2007;88(Pt 3):918–24.
    doi: 10.1099/vir.0.82415-0pubmed: 17325365google scholar: lookup
  60. MacLachlan NJ, Balasuriya UB, Rossitto PV, Hullinger PA, Patton JF, Wilson WD. Fatal experimental equine arteritis virus infection of a pregnant mare: immunohistochemical staining of viral antigens. J Vet Diagn Invest 1996;8(3):367–74.
    pubmed: 8844583
  61. Balasuriya UB, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, Hedges JF. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 2002;20(11–12):1609–17.
    pubmed: 11858869
  62. Bryans JT, Doll ER, Knappenberger RE. An outbreak of abortion caused by the equine arteritis virus. The Cornell veterinarian 1957;47(1):69–75.
    pubmed: 13397180
  63. Hedges JF, Demaula CD, Moore BD, McLaughlin BE, Simon SI, MacLachlan NJ. Characterization of equine E-selectin. Immunology 2001;103(4):498–504.
    doi: 10.1046/j.1365-2567.2001.01262.xpmc: PMC1783268pubmed: 11529941google scholar: lookup
  64. Moore BD, Balasuriya UB, Hedges JF, MacLachlan NJ. Growth characteristics of a highly virulent, a moderately virulent, and an avirulent strain of equine arteritis virus in primary equine endothelial cells are predictive of their virulence to horses. Virology 2002;298(1):39–44.
    pubmed: 12093171
  65. McCollum WH. Vaccination for Equine Viral Arteritis. 2nd International Conference on Equine Infectious Diseases 1969; Paris.
  66. . OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 7th ed. Paris, France: Office International des Epizooties; 2012.
  67. Senne DA, Cabrey EA. Equine viral arteritis: a standard procedure for the virus neutralization test and comparison of results of a proficiency test performed at five laboratories. Proceedings of the 89th Annual Meeting of the United States Animal Health Association 1985.
  68. Wade CM, Giulotto E, Sigurdsson S, Zoli M, Gnerre S, Imsland F. Genome sequence, comparative analysis, and population genetics of the domestic horse. Science 2009;326(5954):865–7.
    doi: 10.1126/science.1178158pmc: PMC3785132pubmed: 19892987google scholar: lookup
  69. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20(9):1297–303.
    doi: 10.1101/gr.107524.110pmc: PMC2928508pubmed: 20644199google scholar: lookup
  70. Wagner HM, Balasuriya UB, James MacLachlan N. The serologic response of horses to equine arteritis virus as determined by competitive enzyme-linked immunosorbent assays (c-ELISAs) to structural and non-structural viral proteins. Comp Immunol Microbiol Infect Dis 2003;26(4):251–60.
    doi: 10.1016/S0147-9571(02)00054-1pubmed: 12676125google scholar: lookup
  71. Balasuriya UB, Rossitto PV, DeMaula CD, MacLachlan NJ. A 29K envelope glycoprotein of equine arteritis virus expresses neutralization determinants recognized by murine monoclonal antibodies. J Gen Virol 1993;74 (Pt 11):2525–9.
    pubmed: 7504076
  72. Sarkar S, Balasuriya UBR, Horohov DW, Chambers TM. Equine herpesvirus-1 suppresses type-I interferon induction in equine endothelial cells. Veterinary Immunology and Immunopathology .
    pubmed: 26275803
  73. Sarkar S, Balasuriya UB, Horohov DW, Chambers TM. The neuropathogenic T953 strain of equine herpesvirus-1 inhibits type-I IFN mediated antiviral activity in equine endothelial cells. Vet Microbiol 2016;183:110–8.
    doi: 10.1016/j.vetmic.2015.12.011pubmed: 26790943google scholar: lookup
  74. Sarkar S, Balasuriya UB, Horohov DW, Chambers TM. Equine herpesvirus-1 infection disrupts interferon regulatory factor-3 (IRF-3) signaling pathways in equine endothelial cells. Vet Immunol Immunopathol 2016;173:1–9.
    doi: 10.1016/j.vetimm.2016.03.009pubmed: 27090619google scholar: lookup
  75. Liu W, Yin L, Chen C, Dai Y. Function modification of SR-PSOX by point mutations of basic amino acids. Lipids Health Dis 2011;10:59.
    doi: 10.1186/1476-511X-10-59pmc: PMC3102630pubmed: 21492481google scholar: lookup
  76. Wu Y, Li Q, Chen XZ. Detecting protein-protein interactions by Far western blotting. Nature protocols 2007;2(12):3278–84.
    doi: 10.1038/nprot.2007.459pubmed: 18079728google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.